Retrospective cohort study compares neoadjuvant therapies for overall survival in locally advanced esophageal squamous cell carcinoma, indicating chemoimmunotherapy may be superior.
Key Points
Chemoimmunotherapy demonstrated a superior 4-year overall survival rate of 91.4%, compared to 60.4% for chemoradiotherapy and 62.5% for chemotherapy.
In a cohort of 625 patients, significant baseline differences were adjusted using inverse probability of treatment weighting for accurate comparison.
Assessment utilized multivariate Cox survival analyses and chi-square tests to evaluate prognostic factors and survival outcomes in treatment groups.
Findings highlight the potential of immunotherapy in multimodal treatment, calling for further investigation in prospective clinical trials.